WebBioniz is a biopharmaceutical company leading the discovery and development of multiple-cytokine inhibitory therapeutics to address immuno-inflammatory diseases and cancer, with an initial focus on orphan diseases. Bioniz leverages expertise in cytokine biology, originating in research conducted at the National Institutes of Health, to create a ... WebJan 4, 2024 · Bioniz Therapeutics is a clinical-stage biopharmaceutical company advancing a pipeline of first-in-class peptide-based multi-cytokine inhibitors for the …
Bioniz Announces Positive End of Phase 2 Meeting with …
WebJul 31, 2024 · May 24, 2024 updated by: Bioniz Therapeutics. A Dose-Ranging Study of Intravenous BNZ132-1-40 in Patients With Large Granular Lymphocyte Leukemia or Refractory Cutaneous T-Cell Lymphoma. This study is an open-label, multi-center, dose-ranging study to characterize the safety, tolerability, preliminary efficacy, and PK/PD of … WebJan 9, 2024 · Spanish drugmaker Almirall has signed an option agreement to acquire Bioniz Therapeutics, a clinical-stage biopharmaceutical company in California.. The move aligns with Almirall’s strategy to support its research and development pipeline and develop a treatment for onco-dermatology and immuno-dermatology.. If executed, the acquisition … rtx 2080 bottleneck tests
Vitiligo Research Foundation Drug Pipelines
WebEquillium, Inc., a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced ... WebBioniz Therapeutics has raised a total of $14.3M in funding over 3 rounds. Their latest funding was raised on Aug 1, 2016 from a Series A round. Bioniz Therapeutics is funded by 4 investors. Takeda Ventures and Signatures Capital are the most recent investors. WebNov 5, 2024 · IRVINE, Calif., Nov. 5, 2024 /PRNewswire/ -- Bioniz Therapeutics, Inc. ("Bioniz") today announced an oral presentation at the 62nd ASH Annual Meeting and Exposition of positive safety and efficacy data from the company's Phase 1/2 clinical study of BNZ-1 for the treatment of refractory cutaneous T-cell lymphoma (rCTCL), a rare, … rtx 2080 clock speed